Oncogenetics
NeoPainel and Super Panel evaluate the same set of 106 genes associated with hereditary predisposition to cancer. NeoPainel offers a targeted strategy; the Super Panel, based on the complete genome, expands the classes of variants and modules analyzed.
The indication must consider personal and family history and, when available, genetic counseling.
Clinical choice
NeoPainel focuses analysis on target genes from the exome. The Super Panel uses the complete genome and adds classes of variants and complementary modules.
Exome base
106 risk genes
A targeted investigation, with high-quality coverage of the genes analyzed and a balance between scope and deadline.
Complete genome base
106 risk genes
Expands investigation to relevant intronic and regulatory variants, minor CNVs and polygenic risk modules, and oncology pharmacogenomics.
Comparative
Both evaluate the same 106 genes related to hereditary predisposition to cancer. The difference lies in the base technology and additional Super Panel modules.
Swipe to compare
| Feature | NeoPainel Cancer | Super Panel |
|---|---|---|
| Genes analyzed | The same 106 genes | The same 106 genes |
| Basic technology | Exome with cured oncology panel | Whole genome (WGS) |
| Clinical use | Targeted strategy for hereditary research | Maximum sensitivity and greater diagnostic power |
| CNVs | Events of 3 or more exons | Events starting from 1 exon |
| PMS2 and Alu insertion in BRCA2 | Specific pipelines | Specific pipelines based on WGS |
| Intronic regions | Focus on coding regions and splice edges | Includes relevant intronic and regulatory regions |
| Infinity VUS | Included | Included |
| PRS and pharmacogenomics | Not included | Breast PRS and oncological pharmacogenomics |
Test content
Esta é a lista completa compartilhada pelo NeoPainel Câncer e pelo Super Painel. The gene content is the same; the technology and analytical breadth are different.
Gene symbols in alphabetical order, according to the current technical content of the tests.
NeoPainel Cancer
Recommended when the objective is to investigate hereditary cancer syndromes in depth in the same 106 genes as the Super Panel, without the additional modules of the whole genome-based strategy.
Technical focus on panel regions, reducing gaps relevant to hereditary predisposition.
Search for gains and losses involving 3 or more exons, in addition to sequence variants in the genes evaluated.
Specific bioinformatics approach for PMS2 and the Alu insertion in the BRCA2 gene.
Super Panel
It brings together monogenic risk, polygenic score and response to medications in a single test, according to the technical scope of each module.
106 risk genes
Relevant coding, intronic and regulatory regions, CNVs from 1 exon and specific pipelines.
PRS
Estimation based on markers and parameters defined by the test.
PGx
Evaluates responses related to 5-FU, opioids, ondansetron and other covered medications.
Science evolves. The interpretation of a variant may also evolve.
All NeoGenomica tests include Infinity VUS for variants of uncertain significance that are reported.
A variant of uncertain significance, or VUS, is a finding for which the available evidence does not yet allow us to conclude whether it is related to the disease. Infinity VUS monitors classification updates even after the report is issued.
Periodically compares reported VUS with new evidence and classifications.
A material change is forwarded for expert review before any communication.
When the reclassification is confirmed and applicable to the case, the responsible team is notified and the report can be updated.
Test day
A clinical flow to investigate hereditary predisposition to cancer and support screening decisions.
The team confirms the indication, family data and the necessary material.
Mouth swab in a home kit or blood in a laboratory.
The genes and modules in the chosen panel undergo specialized analysis and review.
The result organizes findings, clinical implications and follow-up Infinity VUS.
Clinical interpretation
The result presents the main findings, the classification of variants and relevant information for the patient and their family members, as appropriate.
Real excerpt from the NeoReport demonstration environment, cut without personal data.
Frequently asked questions
Both investigate the same gene content for hereditary predisposition to cancer. The difference is in the technology: NeoPainel uses an exomic basis in a targeted strategy; the Super Panel uses whole genome to provide greater sensitivity, including minor CNVs, intronic and regulatory regions, breast PRS, and oncology pharmacogenomics.
The choice considers personal and family history, previous results, the clinical hypothesis and the types of variants that need to be investigated.
sample collection can be carried out using a mouth swab in a home kit or blood, according to team guidance and case requirements.
Yes. The request and clinical data help guide analysis and interpretation of the result.
The reported variants of uncertain significance remain under monitoring. When a relevant reclassification is confirmed, the requesting physician is notified and the report can be updated.
Expert guidance
Our team helps evaluate personal and family history and the objectives of the investigation.
Catalog information
Targeted analysis of genes associated with hereditary predisposition to cancer.
AIP, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CEP57, CHEK2, CTC1, CTNNA1, CYLD, DDB2, DDX41, DICER1, DKC1, EGFR, EGLN1, EPCAM, EXT1, EXT2, FAN1, FH, FLCN, GALNT12, GATA2, GPC3, GREM1, HOXB13, HRAS, KIF1B, KIT, LZTR1, MAX, MDH2, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NSD1, NTHL1, PALB2, PDGFRA, PHOX2B, PMS1, PMS2, POLD1, POLE, POT1, PRF1, PRKAR1A, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, RHBDF2, RNF43, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRAP53, WT1, XRCC2
Medical request, personal and family history, previous results and clinical data to guide the analysis.
Does not include PRS or oncology pharmacogenomics. Intronic and regulatory regions are not its main focus.
Catalog information
Whole-genome-based comprehensive investigation of hereditary predisposition to cancer.
AIP, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, BUB1B, CDC73, CDH1, CDK4, CDKN1B, CDKN2A, CEBPA, CEP57, CHEK2, CTC1, CTNNA1, CYLD, DDB2, DDX41, DICER1, DKC1, EGFR, EGLN1, EPCAM, EXT1, EXT2, FAN1, FH, FLCN, GALNT12, GATA2, GPC3, GREM1, HOXB13, HRAS, KIF1B, KIT, LZTR1, MAX, MDH2, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NSD1, NTHL1, PALB2, PDGFRA, PHOX2B, PMS1, PMS2, POLD1, POLE, POT1, PRF1, PRKAR1A, PTCH1, PTCH2, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, RHBDF2, RNF43, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WRAP53, WT1, XRCC2
Medical request, personal and family history, previous results and clinical data to guide the analysis.
The choice must consider clinical hypothesis and types of variants to be investigated; PRS results depend on the reference population and clinical context.
